Supernus Pharmaceuticals, Inc.

NASDAQ:SUPN

Drug Manufacturers - Specialty & Generic

Healthcare
$28.96 +1.17%

+$0.51 today

Market cap
$6.02B
Beta
0.54
P/E (TTM)
-87.6
EPS (TTM)
-$0.50
52W Low $30.83High $59.68

Volume 2.71M

Average 0.64M

SUPN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Supernus Pharmaceuticals, Inc.NASDAQ: SUPN

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of $29.46M rose 33.2% year over year, ahead of the +18.1% change in trailing-twelve-month research & development. Sequentially, it fell 25.3% from the prior quarter. Over 3 fiscal years it compounded at +12.5% a year.

Context

  • Research & development amounted to 14.8% of revenue in FY2025, down 1.7 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +33.2% holds above the trailing-twelve-month pace of +18.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$29.46M-25.3% QoQ
Last fiscal yearDec 2025
$106.24M-2.4% YoY
LTMJun 2026
$126.09M+18.1% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+33.2%——
1 year-2.4%——
3-year CAGR+12.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
106.24M USD
Year-over-year change
-2.4%
4-year CAGR
+4.1%

Research & Development vs competitors

How SUPN compares with its peers on the latest reported figures

  • SUPN's LTM Jun 2026 research & development of $126.09M is the 2nd highest of the 3 companies compared; the peer median is $215.21M.
  • Its year-over-year change of +18.1% is the lowest of 2, against a peer median of +49.7%.
  • Research & development amounts to 15.2% of revenue for SUPN, versus a peer median of 12.3%.
SUPN Competitors Peer median
Research & Development for SUPN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALKSAlkermes plcLTM Sep 2026$430.42M +49.7%+5.9%24.5%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$126.09M +18.1%+12.5%15.2%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding SUPN) $215.21M+49.7%+5.9%12.3%

Competitors are the stored peer set for SUPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue579.78M667.24M607.52M661.82M718.95M
Cost of Revenue75.06M87.22M83.78M77.91M74.56M
Gross Profit504.71M580.02M523.74M583.91M644.39M
Gross Margin87.1%86.9%86.2%88.2%89.6%
Research & Development90.47M74.55M91.59M108.8M106.24M
Selling, General & Admin304.76M377.22M336.36M335.78M485.56M
Operating Expenses418.69M533.89M529.01M502.25M681.25M
Depreciation & Amortization32.6M85.54M84.86M80.41M91.56M
EBITDA129.19M153.36M90.04M178.28M42.53M
EBITDA Margin22.3%23.0%14.8%26.9%5.9%
Operating Income86.03M46.12M(5.27M)81.67M(36.86M)
Operating Margin14.8%6.9%-0.9%12.3%-5.1%
Interest Income10.57M21.69M10.45M16.2M13.25M
Interest Expense23.42M7.07M2.42M00
Other Income / Expenses(12.85M)14.62M8.04M16.2M(12.17M)
Income Before Tax73.18M60.74M2.77M97.87M(49.03M)
Pre-Tax Margin12.6%9.1%0.5%14.8%-6.8%
Income Tax Expense19.75M32K1.45M24.01M(10.48M)
Net Income53.42M60.71M1.32M73.87M(38.55M)
Net Margin9.2%9.1%0.2%11.2%-5.4%
EPS (Basic)1.011.130.021.34(0.68)
EPS (Diluted)0.981.040.021.32(0.68)
Weighted Avg Shares53.1M53.67M54.54M55.1M56.45M
Weighted Avg Shares (Diluted)54.36M61.68M55.51M55.96M56.45M

Supernus Pharmaceuticals, Inc.

NASDAQ:SUPN

Intrinsic Alpha fair value

Locked

Current Price

$28.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.